Skip to content

Findings on viral rebound discourage quick drug switches in resource-limited settings

Protease inhibitor monotherapy as a maintenance regimen: are we edging towards acceptance?

New EACS guidelines address co-morbidities and diseases of age

Multiple treatment failures occur less frequently but remain associated with high mortality rates in North American cohort

Dual maintenance therapy with atazanavir plus raltegravir sustains viral suppression

Boosted protease inhibitor regimens with 3TC work despite M184V resistance

Switches to second-line ART occurring faster where viral load testing available

Delays in switching treatment: NRTI resistance can be slower to emerge than expected

Second-line treatment: Clinton Foundation announces new price cut